Fresenius Medical Care

Bad Homburg,
Invested through
  • Triodos Impact Mixed Fund - Defensive
  • Triodos Impact Mixed Fund - Neutral
  • Triodos Euro Bond Impact Fund
Asset ClassesCorporate bonds
Impact strategyImpact Equities and Bonds
ISIN codeXS2178769159
Industry groupHealth Care Equipment & Services
Aligned with SDGs
  • Good health and well-being

Fresenius Medical Care (FME) is a leading provider of dialysis services, products and equipment. In doing so, it provides people with chronic kidney diseases with the care they need to live their lives. As products also include dialysis machines, the company is vertically integrated. FME is globally active. Chronic kidney failure is a mature but growing disease as a consequence of the rise of lifestyle diseases (obesities and high blood pressure) on the one hand and higher standards of care in developing economies on the other. Fresenius' roots trace back to the Hirsch pharmacy in Frankfurt am Main. This company was founded in 1462 (!), but Fresenius was officially founded when Hirsch and Dr. Eduard Fresenius started the production of pharmaceuticals back in 1912. FME exists since 1996, when it was partly spun off Fresenius SE (FRE). FRE still has a 31% stake in FME. FRE, in turn, is for 27% owned by the Else Kroner foundation. Fresenius Medical Care has more than 125,000 employees in around 50 countries. The company is headquartered in Bad Homburg, Germany.

Investment rationale

As one of the leading providers of dialysis devices, Fresenius Medical Care has a clear positive impact on society and patients with renal diseases in particular. Fresenius fits our Prosperous and Healthy People theme for several reasons:
- End-stage renal disease (ERSD) is the last stage of chronic kidney disease. Without dialysis or a kidney transplant, ERSD will be lethal because there is no cure for ESRD. Dialysis provides a much more economical and efficient treatment solution compared to kidney transplant. Globally, 1 out of 10 people suffers from some form of chronic kidney disease (CKD). Patients treated for Stage 5 CKD or kidney failure amounted to 4,9 million globally and 800,000 in the US..
- Innovation: the company strives to use its technological edge to manufacture cost-effectively dialysis machines, develop more effective products and treatment methods for renal patients. In 2019, Fresenius acquired NxStage to strengthen its home dialysis business line. Home dialysis can be considered more convenient for patients, thus allowing them to take part in society in a more normal way. In addition, it could potentially contribute to better outcomes (patients tend to respond better to treatments in comfortable environments).
- Finally, the company offers its products at affordable prices in developing markets. This contributes to access and affordability of treatments.
Fresenius Medical Care supports the UN Sustainable Development Goals (SDGs) explicitly, in particular SDG3 Good Health and Well-being by offering high-quality dialysis products and services.